Registered title, quoted from ClinicalTrials.gov
Efficacy and Safety of Chidamide Combined With PD-1 Inhibitor as Maintenance Therapy Following CAR-T Cell Treatment With TP53-Mutated Large B-Cell Lymphoma (LBCL)
An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Tongji Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07934537, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 5
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (5 points)Hide the checklist
18 years to 70 years; sex: all
Registered eligibility fields
Histologically or pathologically confirmed relapsed/refractory aggressive large B-cell lymphoma;
Inclusion criterion 1
Documented TP53 mutation confirmed by genetic testing;
Inclusion criterion 2
Eastern Cooperative Oncology Group (ECOG) performance status ≤2;
Inclusion criterion 5
Known human immunodeficiency virus (HIV) infection;
Exclusion criterion 4
Pregnant or breastfeeding women, or patients of childbearing potential who are unwilling to use contraception;
Exclusion criterion 1
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07934537, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Histologically or pathologically confirmed relapsed/refractory aggressive large B-cell lymphoma;
- Documented TP53 mutation confirmed by genetic testing;
- Age 18-70 years, inclusive; both sexes eligible;
- Patient has elected and is able to complete a CAR T-cell therapy regimen;
- Eastern Cooperative Oncology Group (ECOG) performance status ≤2;
- Life expectancy of at least 3 months;
- Adequate major organ function (within 7 days prior to initiation of study treatment):
(1) Hepatic function: ALT/AST <3 × the upper limit of normal (ULN), and total bilirubin ≤34.2 μmol/L; (2) Renal function: serum creatinine <220 μmol/L; (3) Pulmonary function: oxygen saturation ≥95% on room air; (4) Cardiac function: left ventricular ejection fraction (LVEF) ≥40%;
- Patient is able to swallow and take oral medication;
- Patient has adequate peripheral superficial venous access suitable for intravenous infusion;
- Voluntary participation in the clinical study; full awareness and understanding of the study; written informed consent provided; willingness and ability to comply with and complete all study procedures.
Exclusion Criteria:
- Pregnant or breastfeeding women, or patients of childbearing potential who are unwilling to use contraception;
- Concurrent malignancy of another organ system requiring treatment;
- Uncontrolled coagulation disorder or active bleeding;
- Known human immunodeficiency virus (HIV) infection;
- Currently receiving other antineoplastic therapy (for lymphoma or any other type of tumor);
- Psychiatric illness, or any other known or suspected inability to fully comply with the study protocol;
- Inability to swallow capsules, or any disease significantly affecting gastrointestinal function, such as malabsorption syndrome, prior bariatric (weight-reduction) surgery, inflammatory bowel disease, or partial or complete bowel obstruction;
- Any other concurrent and uncontrolled medical condition that, in the investigator's judgment, would affect the patient's participation in the study.
Quoted from ClinicalTrials.gov, NCT07934537, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07934537, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.